[🇧🇩] Pharmaceutical and Chemical Industry in Bangladesh

[Saif]

ওষুধশিল্পে নতুন নতুন কাজের সুযোগ

গবেষণা ও উদ্ভাবন বাড়াতে ওষুধ প্রতিষ্ঠানগুলো ভিন্ন বিষয়ে পাস করা তরুণদেরকেও কাজে নিচ্ছে।

bangla.thedailystar.net

ওষুধশিল্পে নতুন নতুন কাজের সুযোগ

অলঙ্করণ: আনোয়ার সোহেল/স্টার ডিজিটাল গ্রাফিক্স

দেশের ওষুধশিল্পে বইছে উন্নয়নের হাওয়া। মেধাবী তরুণদের হাত ধরে নতুন নতুন উদ্ভাবনীর মাধ্যমে আরও বিকশিত হচ্ছে এই খাত।

সংশ্লিষ্টদের ভাষ্য, এই খাত এখন রসায়নভিত্তিক ওষুধ থেকে জৈবভিত্তিক ওষুধের দিকে ঝুঁকছে। বিশ্বব্যাপী এসব ওষুধের চাহিদা বেড়ে যাওয়ায় দেশে সদ্য পাস করা তরুণরা এই খাতে নিজেদের ভবিষ্যৎ গড়ার সুযোগ পাচ্ছেন।

গবেষণা ও উদ্ভাবন বাড়াতে ওষুধ প্রতিষ্ঠানগুলো ভিন্ন বিষয়ে পাস করা তরুণদেরকেও কাজে নিচ্ছে।

এই খাতে এখন বায়োটেকনোলজি, জেনেটিক ইঞ্জিনিয়ারিং, বায়োকেমিস্ট্রি ও কেমিক্যাল ইঞ্জিনিয়ারিংয়ের মতো বিষয়ে পড়া তরুণদের চাকরি হচ্ছে। এতদিন শুধু ফার্মেসি বিভাগের স্নাতকরা এই খাতে কাজের সুযোগ পেতেন।

এখন ভিন্ন বিষয়ে পড়া স্নাতকদের নিয়ে ওষুধশিল্প বৈচিত্র্যময় হয়ে উঠছে।

গুণমান নিশ্চিত করতে কর্মকর্তা, নিয়ন্ত্রণ বিশেষজ্ঞ ও বিশ্লেষণ ক্ষমতাসম্পন্ন কর্মীদের নিয়ে দেশের ওষুধশিল্প বিশ্ববাজারে আরও প্রভাবশালী হয়ে উঠছে।

স্কয়ার ফার্মাসিউটিক্যালস, ইনসেপ্টা ফার্মাসিউটিক্যালস, অ্যারিস্টোফার্মা, এসিআই হেলথকেয়ার লিমিটেড, গ্লোব বায়োটেক, বিকন ফার্মাসিউটিক্যালস পিএলসি ও জিসকা ফার্মাসিউটিক্যালসসহ বেশ কয়েকটি শীর্ষ প্রতিষ্ঠান বায়োলজিক্সে প্রচুর বিনিয়োগ করায় এই খাতে উল্লেখযোগ্য প্রবৃদ্ধি দেখা যাচ্ছে।

জৈব উৎস থেকে তৈরি ওষুধের চাহিদা বেড়ে যাওয়ায় এসব প্রতিষ্ঠান এর ওপর বেশি গুরুত্ব দিচ্ছে।

এসিআই হেলথকেয়ার লিমিটেডের ব্যবস্থাপনা পরিচালক ও প্রধান নির্বাহী পরিচালক এম মহিবুজ জামান দ্য ডেইলি স্টারকে বলেন, 'ফার্মেসি, বায়োটেকনোলজি, বায়োকেমিস্ট্রি ও সংশ্লিষ্ট বিষয়ে পাশ করা তরুণদের চাকরির বিশাল সুযোগ তৈরি হয়েছে।'

'এই স্নাতকরা ওষুধ উৎপাদন, মান নিয়ন্ত্রণ, গবেষণা ও বিপণন বিভাগে কাজ করতে পারবেন।'

তবে ওষুধ কারখানার সব ক্ষেত্রে ফার্মেসিতে দক্ষতা অপরিহার্য উল্লেখ করে তিনি আরও বলেন, 'দেশে-বিদেশে মেধাবী তরুণ ফার্মাসিস্টদের ভবিষ্যৎ উজ্জ্বল।'

তিনি মনে করেন, তরুণদের মেধা কাজে লাগিয়ে বাংলাদেশ ওষুধশিল্পে উদ্ভাবন ও স্বনির্ভরতা অর্জনের পাশাপাশি শক্তিশালী অর্থনীতি গড়ে তুলতে পারে।

তার মতে, তরুণরা এই খাতে কাজের সুযোগ পেলে বাংলাদেশ তাদের নেতৃত্বে বৈশ্বিক ওষুধশিল্পে গুরুত্বপূর্ণ ভূমিকা রাখতে পারবে।

ইনসেপ্টা ফার্মাসিউটিক্যালসের মহাব্যবস্থাপক মো. মিজানুর রহমান ডেইলি স্টারকে বলেন, 'গত ২০ বছরে দেশে ওষুধ খাত দশগুণ বেড়েছে। ফার্মেসি, বায়োটেকনোলজি ও সংশ্লিষ্ট শাখায় স্নাতকদের চাকরির সুযোগ অনেক।'

দুই দশক আগে সুযোগ না থাকায় তা সম্ভব হয়নি বলেও জানান তিনি।

তিনি আরও জানান, ব্যাপক প্রবৃদ্ধি ও দক্ষ পেশাদারদের চাহিদা থাকায় অন্যান্য বিষয়ের স্নাতকধারীদের কাছে এই খাত পছন্দের তালিকায় ওপরের দিকে আছে।

ওষুধশিল্পের এই উত্থান নতুন স্নাতকদের পেশা গড়ার পথ তৈরি করেছে। সরবরাহ ব্যবস্থাপনা, মান নিয়ন্ত্রণ, প্রযুক্তিগত পরিষেবা ও বিপণন বিভাগে কাজের সুযোগ বেড়েছে।

মিজানুর রহমান আরও বলেন, 'ওষুধের বাজার ক্রমাগত প্রসারিত হচ্ছে। এই শিল্পের আরও বিকাশের জন্য প্রশিক্ষিত পেশাদারদের প্রয়োজন। ক্রমবিকশিত ওষুধশিল্প তরুণদের জন্য চমকপ্রদ কর্মক্ষেত্র হতে পারে।'

ইউনিমেড ইউনিহেলথ ফার্মাসিউটিক্যালস লিমিটেডের উপ-মহাব্যবস্থাপক মো. আবু জাফর সাদেক ডেইলি স্টারকে বলেন, 'দেশের ওষুধ প্রতিষ্ঠানগুলো রসায়নভিত্তিক ওষুধ থেকে জৈবভিত্তিক ওষুধ তৈরির উদ্যোগ নেওয়ায় বায়োটেকনোলজি ও জেনেটিক ইঞ্জিনিয়ারিংয়ে নতুনদের অবদান রাখার সুযোগ তৈরি করছে।'

এখন দেশের শীর্ষ পাবলিক ও বেসরকারি বিশ্ববিদ্যালয়গুলোয় বায়োটেকনোলজি ও জেনেটিক ইঞ্জিনিয়ারিংয়ে স্নাতক ও স্নাতকোত্তর কোর্স পড়ানো হচ্ছে।

'বছরে প্রায় ৭০০ স্নাতক তৈরি হচ্ছে। ওষুধশিল্পের চাহিদা পূরণে দক্ষ জনশক্তি তৈরি করা হচ্ছে।'

ল্যাবরেটরি, গবেষণা ও উন্নয়ন বিভাগের পাশাপাশি ওষুধ বিপণন বিভাগে নতুনদের কাজের সুযোগ আছে বলে জানান তিনি।

বিশেষায়িত বিভাগগুলো ভালোভাবে পরিচালনা ও পণ্যের প্রচারের জন্য বায়োমেডিসিনে দক্ষ কর্মীর প্রয়োজন।

বাংলাদেশ ওষুধ শিল্প সমিতির (বাপি) তথ্য বলছে, দেশে ১৬০টির বেশি ওষুধ প্রতিষ্ঠান আছে।

একসময় আমদানির ওপর নির্ভরশীল বাংলাদেশ এখন চাহিদার ৯৮ শতাংশ ওষুধ তৈরি করছে।

সংগঠনটির ভাষ্য, প্রায় সাড়ে তিন বিলিয়ন ডলারের ওষুধের বাজার ও বার্ষিক ১২ শতাংশ প্রবৃদ্ধি নিয়ে ওষুধশিল্প উদ্ভাবন ও স্থিতিশীলতার উজ্জ্বল উদাহরণ হয়েছে।

এসিআইয়ের এম মহিবুজ জামান আরও বলেন, 'স্থানীয় চাহিদা মিটিয়ে বাংলাদেশি ওষুধ এখন যুক্তরাষ্ট্র, যুক্তরাজ্য ও ইউরোপসহ বাজারে রপ্তানি হচ্ছে।'

তিনি আরও বলেন, 'এই প্রবৃদ্ধি তরুণদের নতুন কাজের সুযোগ করে দিচ্ছে। দেশের ওষুধ খাতের জন্য নতুন যুগের সূচনা করেছে।'​

 

[Saif]

Drug makers secure growth in H1 on low finance costs, higher sales

Leading drug manufacturers maintained revenue and profit growth year-on-year in the first half of FY25, supported by higher sales amid stability in the forex market. However, efficient management, strong financial positions, and lower finance expenses helped Square Pharmaceuticals and Beximco Ph

thefinancialexpress.com.bd

Drug makers secure growth in H1 on low finance costs, higher sales
Babul Barman
Published :
Feb 10, 2025 00:46
Updated :
Feb 10, 2025 00:46

Leading drug manufacturers maintained revenue and profit growth year-on-year in the first half of FY25, supported by higher sales amid stability in the forex market.

However, efficient management, strong financial positions, and lower finance expenses helped Square Pharmaceuticals and Beximco Pharmaceuticals, among the drug makers, secure a double-digit growth in an adverse business climate.

"Rising income levels and increased health awareness have led to higher spending on medicines," said Akramul Alam, head of research at Royal Capital.

Despite economic headwinds, such as high inflation, currency depreciation, and rising living costs, Bangladesh's pharmaceutical sector has thrived due to strong local demand, self-sufficiency, export growth, cost efficiency, and favorable government policies.

"This resilience allows leading pharmaceutical companies to sustain high revenue and profit growth," said Mr Alam.

The collective revenue of seven major drug manufacturers reached Tk 116 billion in July-December of FY25, a 9.43 per cent increase from the year before.

Their combined profit also rose 6.40 per cent year-on-year to Tk 19.87 billion during the period under review, according to financial statements compiled by The Financial Express.

Square Pharmaceuticals, the largest drug maker in the country, posted a record half-yearly profit of Tk 12.70 billion for the six months through December last year, a 13 per cent year-on-year growth.

Its sales revenue grew 6 per cent year-on-year to Tk 37.72 billion in July-December.

Square Pharmaceuticals attributed its growth to several key factors, including lower finance costs, a boost to domestic demand for healthcare products, and rising exports.

Muhammad Zahangir Alam, chief financial officer (CFO) of Square Pharma, said the drug maker's finance cost had remained zero for the last five years for its zero borrowings.

"Apart from revenue income, our other incomes always support our profit growth," he said.

Square Pharma is strategically expanding its presence in the global markets and diversifying its operations through subsidiaries and associate companies.

Beximco Pharma, another major drug manufacturer, posted an 18 per cent growth in profit to Tk 3.54 billion, supported by higher sales amid growing local demand and export growth.

The company launched new products and expanded international presence, said Iqbal Ahmed, managing director of the company, in a filing on the London Stock Exchange.

Unlike other industries affected by inflation and currency devaluation, the pharmaceutical sector enjoys inelastic demand as medicines are essential regardless of economic conditions, said Mr Alam, of Royal Capital, said.

With a population of over 170 million, Bangladesh has a large and growing healthcare market. The healthcare expenditure per capita was just $30 in 2014, which jumped to more than $58 in 2022.

However, the companies, which could not contain finance costs amid soaring interest rates, were unable to earn expected profits despite higher revenue. In most cases, profitability is squeezed by exorbitant finance expenses.

For example, Renata's profit plunged 39 per cent year-on-year in the first half of FY25 despite 12 per cent revenue growth. Its net finance costs shot up 40 per cent to Tk 792 million in July-December last year.

Renata's short-term and long-term borrowings rose to Tk 11.79 billion in the six months through December last year, from Tk 10.83 billion in June 2024.

Bangladesh exports pharmaceuticals to over 150 countries, including the USA, UK, and EU markets.

Drug exports jumped more than 12 per cent year on-year to $114 million in July-December last year as local drug makers entered new markets and received larger orders.

The industry benefits from LDC (Least Developed Country) privileges, allowing it to produce and export generic drugs without strict patent restrictions, which will continue until 2033, according to Mr Alam.

"High-quality but low-cost production makes Bangladeshi pharmaceutical companies competitive in global markets as well," he added.

The global pharmaceutical industry is expected to grow by 5.80 per cent in the next five years through 2028, while the local industry is expected to grow more than 15 per cent during the time, according to Statista, a global data and business intelligence platform.

The industry contributes more than 1.83 per cent to the country's GDP, according to the Director General of Drug Administration (DGDA). About 80 per cent of the drugs sold are generic and the rest are patented drugs.

Currently, local companies meet 98 per cent of the domestic demand with a market size of Tk 266 billion.​

 

[Bilal9]

Samuda Chemical Complex Limited (SCCL) is a private limited company owned by Mohammad Abul Kalam, Farzana Afroze, Mohammad Mustafa Haider, Rizwana Afroze. SCCL was incorporated in 2006 in Bangladesh under the Companies Act, 1994 and has an authorized capital of BDT 5,000,000,000. It is the largest caustic soda and hydrogen peroxide plant at present in Bangladesh.

[Environment-Friendly Factory]

Samuda Chemical Complex Limited manufactures high quality and competitively priced products i.e. Hydrogen peroxide, Caustic Soda, Liquid Chlorine, Hydrochloric acid, Sodium Hypochlorite, calcium Carbonate, Filler compound and Chlorinated Paraffin Wax, which deliver outstanding value to its customers. The Company’s products and production processes are benchmarked with the best of global touchstones and meet the most rigorous international specifications.

[Dhaka Plant @ Munshiganj Beside Meghna River]

SCCL’s Products go into numerous end-use applications in a variety of industries: paper and pulp, textiles, pharmaceuticals, food, tanning, water treatment, plastics, footwear, Detergent and petroleum refining. Leaving its mark on the local market, the company also exports its products to other ountries in South Asia.

[Chattrogram Plant @Alamin Baria]

Since its inception as the first company in Bangladesh to produce Hydrogen peroxide upto 70% concentration, SCCL has been continuously raising the bar in technological competence and gaining recognition as an innovator. Overall production capacity of Samuda Chemical Complex Limited is 650-50 MT per day.


The company has an enduring commitment to protecting and enhancing the environment, serving and improving the communities in which it functions and adhering to the highest ethical standards of corporate behavior.

 

[Saif]

Pharma industry has a bright future

Foreign participants at the 16th Asia Pharma Expo foresee a bright future for Bangladesh’s pharmaceutical industry, given its continuous product development and expanding global footprint.

www.thedailystar.net

Pharma industry has a bright future
Foreign participants say at Asia Pharma Expo

Foreign participants at the 16th Asia Pharma Expo foresee a bright future for Bangladesh's pharmaceutical industry, given its continuous product development and expanding global footprint.

"Bangladesh's pharmaceutical sector has shown really impressive development. The country manufactures medicines of global standard and has developed a highly skilled workforce," said Lashimikanth Enaganti, assistant general manager of Smilax Laboratories Limited, India.

He was speaking to The Daily Star at the venue of the 16th Asia Pharma Expo and Asia Lab Expo, organised by the Bangladesh Association of Pharmaceutical Industries at the Bangladesh-China Friendship Exhibition Centre in Purbachal.

Enaganti praised Bangladesh's progress, highlighting its high-quality medicine production and skilled workforce. His company, which produces 60 types of active pharmaceutical ingredients (APIs), exports to 10 leading Bangladeshi pharmaceutical firms. He sees this growth as mutually beneficial for both countries.

Deepak Shah, director at Mumbai-based Titan Laboratories Pvt Ltd, echoed this observation. His company, a supplier of 20 types of APIs, has been exporting to Bangladesh for over two decades and has witnessed the sector's significant progress.

"Our export volume to Bangladesh is increasing," he added.

Monjurul Alam, CEO of Beacon Medicare Limited, said that Bangladesh imports around $1.2 billion worth of APIs annually. He emphasised that events like the Asia Pharma Expo help local companies source new ingredients and advanced machinery, supporting industry expansion.

International suppliers have also noted the sector's development. Klaus N Moller, head of sales and service at Germany's Process Technology Pharma, has been supplying pharmaceutical equipment to Bangladesh for 24 years. Initially providing small-scale equipment, his company's sales grew alongside the industry's expansion.

Moller also mentioned that his company has set up a factory for commissioning.

Halimuzzaman, managing director of Healthcare Pharmaceuticals, noted that Bangladesh imports approximately $500 million worth of pharmaceutical machinery, primarily from Europe, to ensure quality. He emphasised the importance of the expo in connecting local manufacturers with cutting-edge technology.

The event was inaugurated by Zakia Sultana, senior secretary of the Ministry of Industries. She underscored Bangladesh's ability to meet 98 percent of its pharmaceutical demand through local production while exporting to 157 countries.

However, she acknowledged the challenge of API import dependence. To address this, the government has established an API Industrial Park in Gazaria, Munshiganj, with the aim of boosting local API production, reducing import reliance, and cutting costs.

"With 27 pharmaceutical companies allotted plots, the park is expected to enhance research, attract foreign investment, and prepare the industry for Bangladesh's LDC graduation in 2026," Sultana said.

She encouraged stakeholders to capitalise on these opportunities, pointing out that capturing even 1 percent of the $400 billion global generic drug market could generate $4 billion in export revenue.

Md Shameem Haidar, director general of the Directorate General of Drug Administration, highlighted the pharmaceutical sector's contribution as the second-largest revenue generator for the government.

Initially focused on domestic demand, the industry now exports to 160 countries, including highly regulated markets such as the US, UK, Canada, Australia, and the EU.

He noted that leading Bangladeshi firms have obtained major Good Manufacturing Practice (GMP) accreditations, including US FDA certification. Additionally, Bangladesh's National Drug Control Laboratory (NCL) is progressing toward achieving WHO Maturity Level 3 recognition.

Haidar emphasised the expo's role in fostering collaboration, innovation, and technological advancements in pharmaceutical manufacturing and research.

Md Saidur Rahman, secretary to the Health Services Division, credited local pharmaceutical companies for making medicines affordable and ensuring quality healthcare. He acknowledged their contributions to Bangladesh's health sector through the production of world-class medicines.

Speaking at the event, Abdul Muktadir, president of BAPI, expressed concern over the ongoing gas crisis, saying it affects the cost-effectiveness of pharmaceutical products.

This year's expo is being participated in by 800 companies from 32 countries, including the US, China, UK, Germany, Malaysia, India, Thailand, Italy, Japan, Switzerland, Taiwan, and Ireland.

The event showcases advancements in pharmaceutical processing and packaging, biotech lab equipment, API manufacturing, and contract pharmaceutical manufacturing.

By bringing together domestic and international entrepreneurs, the expo provides valuable insights into the latest pharmaceutical technologies, equipment, and raw materials.

The three-day Asia Pharma Expo will conclude on February 14, remaining open daily from 10:00am to 6:00pm.

With Bangladesh already fulfilling 98 percent of its domestic pharmaceutical needs before exporting to 157 countries, the country's role in the global pharma industry continues to strengthen.​

 

[Saif]

Curbing drug companies' sway on doctors

The healthcare sector of the country is increasingly plagued by unethical practices, making regulatory intervention a formidable challenge. Among these concerns, the growing nexus between pharmaceutical companies and practising physicians has become particularly alarming. While drug promotion throu

thefinancialexpress.com.bd

Curbing drug companies' sway on doctors
Published :
Feb 28, 2025 00:07
Updated :
Feb 28, 2025 00:07

The healthcare sector of the country is increasingly plagued by unethical practices, making regulatory intervention a formidable challenge. Among these concerns, the growing nexus between pharmaceutical companies and practising physicians has become particularly alarming. While drug promotion through medical representatives is not a new phenomenon, its character has significantly changed. Previously, pharmaceutical representatives primarily provided doctors with sample medicines and relevant information on pharmacological composition, potential side effects, and overall efficacy. However, recent reports suggest that this practice has escalated to an unethical level, where pharmaceutical companies wield substantial influence over doctors' discretion to prescribe medicines.

It is widely reported that drug companies frequently influence medical prescriptions by offering incentives to doctors, raising serious ethical and medical concerns that largely remain unchecked. Sales representatives from these companies are often seen waiting outside clinics and hospitals, eager to interact with doctors. In some cases, they go as far as to monitor prescriptions by taking screenshots with smartphones as patients exit medical facilities, ensuring that their drugs are being promoted. More troubling is the allegation that some doctors prescribe unnecessary medications that have little or no relevance to the patient's actual condition. This practice not only exploits patients financially but also raises significant health risks by exposing them to unnecessary side effects and potential complications.

The deeper issue is that many doctors acknowledge this malpractice but remain reluctant to speak publicly against it. Some admit that the practice has become deeply ingrained in the medical community, where peer pressure and the fear of professional isolation discourage opposition. On the other hand, pharmaceutical marketing professionals justify their promotional strategies by citing industry pressures and competition. This commercialised approach to medicine undermines the fundamental ethics of healthcare.

Despite growing awareness, the undue influence of pharmaceutical companies on physicians remains pervasive. Addressing this issue requires a combination of stricter regulations, ethical enforcement, and systemic reforms. Experts suggest that one potential solution is to promote the prescription of generic drugs over branded ones, as this would reduce the incentives tied to many pharma companies. Additionally, updating and strictly implementing the country's drug policy is essential to regulate interactions between pharmaceutical companies and healthcare providers. Without decisive actions, the integrity of the healthcare system will continue to be compromised, leaving patients vulnerable to commercial exploitation rather than allowing them to receive the genuine medical care they deserve. Moreover, the role of regulatory bodies and professional organisations must be strengthened to curb these unethical practices effectively. Medical associations should take a firm stance against such influences and encourage doctors to adhere to ethical guidelines when prescribing medication. Public awareness campaigns can also play a crucial role in educating patients about their rights and the dangers of unnecessary prescriptions. If patients are better informed, they can question and verify the necessity of prescribed medicines, reducing the blind dependence on prescriptions influenced by pharmaceutical companies. Transparency in the healthcare sector, supported by government oversight, is vital for ensuring that medical decisions are driven by patient needs rather than commercial interests.​

 

[Saif]

Govt moves to encourage cancer drugs making

The tax authority has reduced the tax at source on the import of raw materials for the manufacture of cancer-related drugs, a development that is expected to reduce production costs and prices.

www.thedailystar.net

Govt moves to encourage cancer drugs making

The tax authority has reduced the tax at source on the import of raw materials for the manufacture of cancer-related drugs, a development that is expected to reduce production costs and prices.

In a notification issued on Sunday, the National Board of Revenue (NBR) said it would collect 2 percent tax at source on the import of the ingredients of oncology medicines, down from 5 percent.

A senior official of the tax administration said they slashed the tax based on recommendations from the health ministry.

"This will be helpful for oncology product manufacturers and end users, as production costs will decrease, making the products more affordable," said Aminul Islam Khan, chairman and managing director of Ziska Pharmaceuticals Ltd.

This will be helpful for oncology product manufacturers and end users, as production costs will decrease, said sector people

The NBR's move comes at a time when the prevalence of cancer is growing in Bangladesh, and a number of pharmaceutical companies are manufacturing oncology products for both domestic and export markets.

At present, the cancer prevalence in the country is 106 cases per 100,000 population, with the prevalence being higher among males.

In Bangladesh, cancer is responsible for 11.9 percent of all deaths annually, according to a new study by the Bangabandhu Sheikh Mujib Medical University last month.

The study revealed that 52.9 new cases are reported per 100,000 people every year.

Khan said the price of oncology products in Bangladesh is lower than in any other country because the nation can produce generic versions of medicines without patent restrictions.

For this reason, cancer patients from different countries seek Bangladeshi oncology products at a lower cost, he added.

Oncology products made in Bangladesh are exported to advanced countries, including Europe and Australia, due to competitive prices and high quality, he said.​

 

[Saif]

Square Pharma’s Tapan Chowdhury to buy over Tk 32 crore worth of shares

Tapan Chowdhury, managing director of Square Pharmaceuticals, has expressed his intention to purchase 15 lakh shares of the company—the largest drug producer of the country—valued at over Tk 32 crore at the current market price.

www.thedailystar.net

Square Pharma’s Tapan Chowdhury to buy over Tk 32 crore worth of shares
He will buy 15 lakh shares at prevailing market prices

Tapan Chowdhury, managing director of Square Pharmaceuticals, has expressed his intention to purchase 15 lakh shares of the company—the largest drug producer of the country—valued at over Tk 32 crore at the current market price.

Chowdhury, also a sponsor of the company, plans to acquire the shares at the prevailing market price in both the public and block markets through the Dhaka Stock Exchange (DSE) within the next 30 working days, Square Pharmaceuticals said in a disclosure on the premier bourse's website.

As of 12:42pm, Square Pharmaceuticals' shares had declined by 0.14 percent to Tk 216.8 on the DSE, compared to the previous day's closing price of Tk 217.1.

Chowdhury's announcement comes two weeks after a similar declaration by Anjan Chowdhury, another sponsor director of Square, who also intended to buy 15 lakh shares, valued at Tk 32 crore at the market price at that time.

As of November 30 last year, Tapan Chowdhury held a 9.47 percent stake in Square Pharmaceuticals, a major concern of Square Group. Following the purchase, his total stake in the company will increase to 9.65 percent.

As of January this year, sponsors and directors collectively held 42.91 percent of Square Pharmaceuticals' shares, while the public owned 27.67 percent.

Foreign and institutional investors held 15.54 percent and 13.88 percent, respectively.

The pharmaceutical producer and exporter's net profit rose 26 percent year-on-year to Tk 660 crore in the October-December period of the 2024-25 fiscal year.

Higher income from investments and increased profits from associated companies contributed to Square Pharmaceuticals' earnings growth.

In the first half of the 2024-25 financial year, the company recorded a profit of Tk 1,269 crore, up 13 percent year-on-year, according to its second-quarter financial statement.

However, in the 2023-24 financial year, Square Pharmaceuticals' profit after tax declined by 5.34 percent year-on-year to Tk 1,559 crore.​

 

[Saif]

Pharma exports rise, but Feb slump raises eyebrows

Bangladesh’s pharmaceutical exports posted steady growth in the first eight months of the current fiscal year, buoyed by rising demand from developed markets, though a sharp decline in February raised concerns, industry experts said.

www.thedailystar.net

Pharma exports rise, but Feb slump raises eyebrows

Bangladesh's pharmaceutical exports posted steady growth in the first eight months of the current fiscal year, buoyed by rising demand from developed markets, though a sharp decline in February raised concerns, industry experts said.

The sector earned $145.46 million from July to February of fiscal year (FY) 2024-25, a 7.1 percent increase from $135.81 million in the same period a year earlier, according to data from the Export Promotion Bureau (EPB).

Industry insiders attributed the growth to the increasing popularity of Bangladeshi pharmaceuticals in key Western markets, including the United States, Australia and Europe.

In February alone, the sector generated $13.02 million, lower than the $16.81 million recorded in the same month of the previous fiscal year, marking a 22.6 percent decline.

The drop was largely driven by recent cuts in US foreign aid and a temporary halt in medicine shipments to Vietnam and Cambodia, where business activities slowed during New Year celebrations, industry insiders said.

"Our exports have grown due mainly to increasing orders from the US, Unicef and the World Health Organization," said Muhammad Zahangir Alam, chief financial officer at Square Pharmaceuticals, one of Bangladesh's leading drug manufacturers and exporters.

Regarding the February decline, he said month-to-month fluctuations in shipments are common and depend on the timing of export orders.

"We have long-term agreements in place to supply products to our buyers, so such fluctuations do not largely impact our exports," he added.

Alam also said that Square Pharma does not accept export orders on credit from new buyers as part of its policy to ensure payment security.

Mohammad Ali Nawaz, chief financial officer at Beximco Pharmaceuticals Ltd, said export orders have remained steady, with continuous direct supply to the US government.

"During the first eight months of the current fiscal year, we have received strong export orders, including from developed markets such as the US, South Africa and Australia," he said.

Nawaz noted that the company's export orders have been growing consistently, reflecting a positive trend in international business.

"This steady growth in exports is a strong indication of the company's resilience and adaptability in a competitive global market," he said.

Monjurul Alam, chief executive officer of Beacon Medicare Ltd, a unit of Beacon Pharmaceuticals, said that although EPB data shows sluggish exports in recent months, pharmaceutical shipments are actually rising.

He explained that shipments usually slow in January and February, as exports to Vietnam and Cambodia, two key importers, pause during this period.

"This seasonal slowdown explains the slight drop in February export figures," he said.

EPB data shows pharmaceutical exports fell 22.6 percent in February from January.

Alam expects exports to rebound in April as shipments to Vietnam and Cambodia resume. "There is no reason to be concerned about negative figures for one or two months of shipments," he said.

While pharmaceutical export figures are not large, they are important for the country's image and the industry, he added.

Ananta Saha, international business manager at Renata Ltd., echoed Alam's sentiments, saying export orders have remained steady.

However, he noted that export growth has not been as fast as expected.

Despite the slower pace, Renata remains optimistic about its long-term international business prospects, he added.

The case for Incepta Pharmaceuticals Ltd. is different, as the impact of US aid cuts directly affected its exports.

Arefin Ahmed, executive director at Incepta Pharmaceuticals, said the company was significantly affected by the recent cancellation of US aid funding.

"We regularly supply a large quantity of medicine to several countries, including Bangladesh, under the US aid programme. However, the sudden cancellation of this funding forced us to cancel two major vaccine shipments," he said.

The canceled shipment comprised 2 million injection doses worth $2 million.

Ahmed said USAID has been a loyal customer of Incepta, which is Bangladesh's second-largest generic pharmaceutical producer after Pfizer, the U.S.-based pharmaceutical giant.

The unexpected cancellation disrupted operations, affecting both revenue and the company's commitment to supplying critical medicines, he said.​

 

[Bilal9]

Pharma exports rise, but Feb slump raises eyebrows

Bangladesh’s pharmaceutical exports posted steady growth in the first eight months of the current fiscal year, buoyed by rising demand from developed markets, though a sharp decline in February raised concerns, industry experts said.

www.thedailystar.net

Pharma exports rise, but Feb slump raises eyebrows

View attachment 15291

Bangladesh's pharmaceutical exports posted steady growth in the first eight months of the current fiscal year, buoyed by rising demand from developed markets, though a sharp decline in February raised concerns, industry experts said.

The sector earned $145.46 million from July to February of fiscal year (FY) 2024-25, a 7.1 percent increase from $135.81 million in the same period a year earlier, according to data from the Export Promotion Bureau (EPB).

Industry insiders attributed the growth to the increasing popularity of Bangladeshi pharmaceuticals in key Western markets, including the United States, Australia and Europe.

In February alone, the sector generated $13.02 million, lower than the $16.81 million recorded in the same month of the previous fiscal year, marking a 22.6 percent decline.

The drop was largely driven by recent cuts in US foreign aid and a temporary halt in medicine shipments to Vietnam and Cambodia, where business activities slowed during New Year celebrations, industry insiders said.

"Our exports have grown due mainly to increasing orders from the US, Unicef and the World Health Organization," said Muhammad Zahangir Alam, chief financial officer at Square Pharmaceuticals, one of Bangladesh's leading drug manufacturers and exporters.

Regarding the February decline, he said month-to-month fluctuations in shipments are common and depend on the timing of export orders.

"We have long-term agreements in place to supply products to our buyers, so such fluctuations do not largely impact our exports," he added.

Alam also said that Square Pharma does not accept export orders on credit from new buyers as part of its policy to ensure payment security.

Mohammad Ali Nawaz, chief financial officer at Beximco Pharmaceuticals Ltd, said export orders have remained steady, with continuous direct supply to the US government.

"During the first eight months of the current fiscal year, we have received strong export orders, including from developed markets such as the US, South Africa and Australia," he said.

Nawaz noted that the company's export orders have been growing consistently, reflecting a positive trend in international business.

"This steady growth in exports is a strong indication of the company's resilience and adaptability in a competitive global market," he said.

Monjurul Alam, chief executive officer of Beacon Medicare Ltd, a unit of Beacon Pharmaceuticals, said that although EPB data shows sluggish exports in recent months, pharmaceutical shipments are actually rising.

He explained that shipments usually slow in January and February, as exports to Vietnam and Cambodia, two key importers, pause during this period.

"This seasonal slowdown explains the slight drop in February export figures," he said.

EPB data shows pharmaceutical exports fell 22.6 percent in February from January.

Alam expects exports to rebound in April as shipments to Vietnam and Cambodia resume. "There is no reason to be concerned about negative figures for one or two months of shipments," he said.

While pharmaceutical export figures are not large, they are important for the country's image and the industry, he added.

Ananta Saha, international business manager at Renata Ltd., echoed Alam's sentiments, saying export orders have remained steady.

However, he noted that export growth has not been as fast as expected.

Despite the slower pace, Renata remains optimistic about its long-term international business prospects, he added.

The case for Incepta Pharmaceuticals Ltd. is different, as the impact of US aid cuts directly affected its exports.

Arefin Ahmed, executive director at Incepta Pharmaceuticals, said the company was significantly affected by the recent cancellation of US aid funding.

"We regularly supply a large quantity of medicine to several countries, including Bangladesh, under the US aid programme. However, the sudden cancellation of this funding forced us to cancel two major vaccine shipments," he said.

The canceled shipment comprised 2 million injection doses worth $2 million.

Ahmed said USAID has been a loyal customer of Incepta, which is Bangladesh's second-largest generic pharmaceutical producer after Pfizer, the U.S.-based pharmaceutical giant.

The unexpected cancellation disrupted operations, affecting both revenue and the company's commitment to supplying critical medicines, he said.​

February slump is a blip and nothing to worry about.

We should reduce dependency of pharma exports to any single or regional market (Vietnam and Cambodia), spread out risks evenly.

 

[Bilal9]

Renata Approved to Export Parkinson’s Drug to Europe​

​

1 min read​

On Sep 4, 2024

Share
Renata, a leading Bangladeshi pharmaceutical company, has successfully secured approval to export its Cabergoline 0.5mg tablets to several European countries. The drug, used in treating conditions like Parkinson’s disease and hyperprolactinemia, has been cleared through the EU Decentralized Procedure (DCP), enabling its sale across a range of European markets.

The company made the announcement in a filing with the Dhaka Stock Exchange (DSE) on September 2, confirming that the approval grants access to markets including Ireland, France, Portugal, Italy, Denmark, Sweden, the Netherlands, Norway, and Spain. “This important milestone highlights Renata’s commitment to expanding its presence in Europe by developing and delivering high-quality, low-dose, high-potency medicines,” the company stated in its DSE announcement.

The 0.5mg Cabergoline tablets will be produced at Renata’s advanced UK MHRA-approved facility, which follows stringent quality control standards. The facility is designed to meet the specific requirements of the European market, ensuring the medication is produced to the highest quality standards. Renata also confirmed that the product will be distributed across Europe through a network of strategic partnerships, allowing widespread patient access to the treatment.

In addition to the European expansion, Cabergoline is already available in Bangladesh under the brand name Cabolin. This approval further cements Renata’s global standing in the pharmaceutical sector. Notably, last year Renata’s European subsidiary, Renata Pharmaceuticals (Ireland) Limited, received approval from the EU and German regulators to launch Cabergoletten 1mg and 2mg tablets for Parkinson’s treatment in those markets. Renata’s continued success in expanding its product reach reflects its growing influence and capability in the global pharmaceutical industry.

 

[Saif]

Impact on pharmaceutical sector

BANGLADESH’S pharmaceutical sector has experienced remarkable growth over the past few decades, transforming from a largely import-dependent industry to a thriving sector that meets most of the domestic demand for medicines. The sector is characterised by intense competition among local players...

www.newagebd.net

Impact on pharmaceutical sector
Ziauddin Hyder 21 April, 2025, 00:00

BANGLADESH’S pharmaceutical sector has experienced remarkable growth over the past few decades, transforming from a largely import-dependent industry to a thriving sector that meets most of the domestic demand for medicines. The sector is characterised by intense competition among local players, with a mix of large and small manufacturers operating in the market, transforming Bangladesh into one of the leading pharmaceutical markets in South Asia.

Bangladesh produces medicines to meet around 97 per cent of its domestic demand, with local manufacturers supplying a wide range of essential and non-essential drugs. Furthermore, the sector has been increasingly export-oriented, with Bangladeshi pharmaceutical proucts being shipped to more than 150 countries, including regulated markets such as the United States and Europe.

The growth of Bangladesh’s pharmaceutical sector can be attributed to several policy measures, including the National Drug Policy, the Drugs Control Ordinance 1982 and the patent exemption. While the national policy helped to build domestic manufacturing capacity in the pharmaceutical sector, Bangladesh’s status as a developing nation granted it a period of patent exemption under the British Patents and Design Act 1911, allowing domestic firms to produce generic versions of patented drugs at reduced costs. Other policy measures that contributed to the growth of this sector include tax incentives and holidays, import duty exemption, research and development support, value-added tax waiver, foreign currency assistance and National Active Pharmaceutical Ingredients and Laboratory Reagents Production and Export Policy introduced in 2018 to encourage API production and provides incentives such as cash incentives for producers who add value to their products.

Bangladesh’s graduation from the least developed country status in 2026 will significantly hurt this growing industry compared with the apparel sector for several reasons. As a result of this graduation, Bangladesh will lose the Trade-Related Aspects of Intellectual Property Rights transition period, which allowed the country to produce generic versions of patented medicines. This may lead to increased competition from multinational companies and potential loss of market share for local manufacturers. The apparel sector is not heavily reliant on intellectual property protection. While both he sectors are export-oriented, the pharmaceutical sector’s export may be more vulnerable to changes in international trade agreements and patent laws and may face increased competition from multinational companies, potentially leading to reduced market share and profitability.

The graduation will require Bangladesh to comply with stricter regulatory standards, including good manufacturing practices and good distribution practices. This may necessitate investments in infrastructure and quality control, which will add additional burden to the export-oriented pharmaceutical industry, as the country will no longer be eligible for preferential treatment under certain trade agreements. Furthermore, local manufacturers may face increased competition from multinational companies, potentially leading to market share loss and reduced profitability.

In order to mitigate risks to the pharmaceutical sector associated with the LDC graduation, Bangladesh needs to strengthen its regulatory framework to ensure compliance with international standards, including good manufacturing practices and good distribution practices. The local manufacturers also need to invest in research and development to develop products and stay competitive. This increased investment should be combined with training and capacity-building programmes for local manufacturers to enhance their competitiveness and compliance with international standards. Finally, the government needs to negotiate favourable trade agreements with other countries to maintain preferential market access for Bangladeshi pharmaceutical products.

In conclusion, graduation from the LDC status presents both challenges and opportunities for the pharmaceutical sector in Bangladesh. By strengthening the regulatory framework, investing in research and development and negotiating favourable trade agreements, Bangladesh can mitigate the negative impact and capitalise on the opportunities arising from graduation.

Dr Ziauddin Hyder is an adviser to the Bangladesh Nationalist Party chairperson and former senior health and nutrition specialist, World Bank Group.​

 

[Saif]

The promises and pressures of Bangladesh’s pharma industry

There is no doubt that Bangladesh’s pharmaceutical industry has shown remarkable potential.

www.thedailystar.net

The promises and pressures of Bangladesh’s pharma industry

VISUAL: ANWAR SOHEL

The pharmaceutical sector in Bangladesh, now valued at more than $3.5 billion (as of 2023), stands as one of the most compelling narratives of progress in the country's economic landscape. From meeting 98 percent of domestic medicine needs to reaching over 150 countries with exports, this industry has evolved into a cornerstone of both national health and economic resilience. Our pharmaceutical companies are not only providing affordable healthcare across the country, but they are also gradually earning recognition on the global stage. As we approach the country's graduation from the Least Developed Country (LDC) status in November 2026, there is a growing need for the industry to adapt to new global norms and challenges.

This transformation has not happened overnight. Decades ago, Bangladesh was heavily reliant on imported medicines. Today, it produces nearly all essential drugs domestically, including life-saving ones such as antibiotics, insulin, and cancer treatments. With a population exceeding 170 million, the demand for accessible and cost-effective healthcare continues to grow. The local pharmaceutical sector has stepped up in response, resulting in improved health outcomes and a strengthened national supply chain. Alongside this domestic impact, the country has extended its pharmaceutical reach to international markets. In FY2023-24, pharmaceutical exports were valued at $205.48 million, registering a 17.14 percent growth. Bangladeshi medicines reached regions in Africa, Southeast Asia, and even entered regulated markets like the United States and Europe. A key contributor to this success has been the industry's commitment to upgrading its technological capabilities and investing in more advanced manufacturing practices, including the production of biosimilars and complex generics.

Decades ago, Bangladesh was heavily reliant on imported medicines. Today, it produces nearly all essential drugs domestically, including life-saving ones such as antibiotics, insulin, and cancer treatments. With a population exceeding 170 million, the demand for accessible and cost-effective healthcare continues to grow. The local pharmaceutical sector has stepped up in response, resulting in improved health outcomes and a strengthened national supply chain.

Underlying this growth has been a strategic use of policy flexibility under the World Trade Organization's (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement. Bangladesh currently benefits from a waiver that allows the production of generic versions of patented drugs without the need for costly licensing. This policy has provided a significant competitive edge in global markets. However, this advantage will come to an end after November 2026. Once the waiver expires, companies will be required to obtain a licence to produce patented medications. This shift is likely to increase production costs, potentially affecting the affordability of life-saving drugs. At the same time, global pharmaceutical giants may reclaim market space that Bangladeshi firms have started to occupy.

The expiration of the TRIPS waiver is just one aspect of a broader set of challenges that the industry will need to address. One of the most pressing issues is the overwhelming dependency on imported raw materials, specifically active pharmaceutical ingredients (API). More than 95 percent of these are sourced from countries like India and China, which makes the entire production chain vulnerable to disruptions and external price fluctuations. Beyond sourcing materials, the path to entering highly regulated export markets is filled with obstacles. Certifications for compliance with international standards can be expensive and time-consuming, often delayed further by bureaucratic inefficiencies at home. Building new manufacturing facilities or upgrading existing ones also tends to move slowly under the current administrative frameworks.

Another critical concern lies in the gap between the industry's technical demands and the available talent pool. Modern pharmaceutical manufacturing, especially in fields like biologics and hormone-based treatments, requires specialised training and a strong foundation in both research and engineering. Although progress has been made, there is still a long road ahead in terms of workforce development. Infrastructure development has not kept pace either. Projects like the long-awaited API Industrial Park have faced repeated delays, often tied to policy inconsistencies and administrative bottlenecks. As Bangladesh graduates from the LDC status, it is also set to lose various trade privileges, including duty-free access to several export markets. This shift may erode the cost competitiveness that has so far helped our pharmaceutical products find a foothold abroad.

Still, despite these hurdles, there is reason to be optimistic. While highly regulated markets have always attracted the most attention, there are numerous unregulated and semi-regulated markets in regions like Africa, Latin America, and parts of Asia that offer immediate opportunities. These areas typically have fewer entry barriers and a strong demand for affordable, quality medicines. Accelerating the establishment of the API Industrial Park and supporting local production capabilities can significantly reduce dependency on imported raw materials, making the industry more resilient and cost-effective in the long run. With global demographics shifting and an ageing population driving the need for drugs targeting chronic illnesses and cancer, Bangladesh has a timely opportunity to develop its expertise in biosimilars and niche therapeutic areas through targeted investment in research and development.

From being heavily dependent on imports to becoming a growing exporter of essential medicines, Bangladesh's pharmaceutical story is one of resilience and reinvention. As the country enters a more competitive and complex global trade environment, the industry must prepare to meet new expectations.

Collaboration between the public and private sectors will be key in unlocking the next phase of innovation. Government incentives, policy support, and funding for research facilities, when combined with private sector efficiency and ambition, can create a powerful engine for long-term growth. As part of this preparation, the government can also explore negotiating an extension to the TRIPS transition period to allow more time for adaptation. Building frameworks for patent access, including participation in global patent pools or voluntary licensing agreements, can help maintain the affordability and availability of newer medicines. Additionally, streamlining regulatory approval processes, simplifying land acquisition, and providing tax incentives for research activities would send a strong signal to investors and innovators alike.

There is no doubt that Bangladesh's pharmaceutical industry has shown remarkable potential. But in order to sustain this momentum, we will need forward-looking policies, strong coordination across stakeholders, and a willingness to confront the industry's structural weaknesses. This is a moment to align regulatory architecture, engineering talent, research capabilities, internal compliance, and business strategy for the greater good.

From being heavily dependent on imports to becoming a growing exporter of essential medicines, Bangladesh's pharmaceutical story is one of resilience and reinvention. As the country enters a more competitive and complex global trade environment, the industry must prepare to meet new expectations. With strategic investments, collaborative thinking, and confidence in our own capabilities, there is every reason to believe that Bangladesh can continue to grow as a global provider of affordable, high-quality medicine. On the other hand, the industry needs more proactive hand-holding and policy support from the government.

Mamun Rashid, an economic analyst, is chairman at Financial Excellence Ltd and founding managing partner of PwC Bangladesh. He has played a pivotal role in establishing pharmaceutical and healthcare facilities in Bangladesh's private sector over the last 35 years.​